Pharmacokinetic interaction safety of combination of elagolix and digoxin in healthy women: An open-label, two period crossover study

Trial Profile

Pharmacokinetic interaction safety of combination of elagolix and digoxin in healthy women: An open-label, two period crossover study

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2017

At a glance

  • Drugs Elagolix (Primary) ; Digoxin
  • Indications Endometriosis; Uterine leiomyoma
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 25 Sep 2017 New trial record
    • 01 Sep 2017 Results published in the Clinical Pharmacology in Drug Development: 2017 Annual Meeting of the American College of Clinical Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top